Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in adults with perennial allergic rhinitis
2023-508817-18-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in perennial rhinitis comparing Lebrikizumab + mometasone furoate with Placebo for lebrikizumab + mometasone furoate (2 arms). Primary endpoint: Mean change from baseline in Total Nasal Symptom Score at Week 16. Planned start Oct 2024; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on 2023-508817-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508817-18-00.